West Pharma Q2 net sales $771M (+6.6%); cuts FY2022 guidance on FX and COVID decline

WEST PHARMACEUTICAL SERVICES INC

2022-Q2 EPS reported $4.77 revenue$1,491,300,000

Q2 net sales $771.3M (+6.6% reported, +13.1% organic); reported EPS $2.48, adjusted EPS $2.47.
Proprietary Products segment sales $653.7M (+11.3%, organic +18.3%) led by high-value components and devices.
Contract-Manufactured Products sales $117.8M (-13.6%, organic -8.9%) on lower diagnostic device component sales.
FY2022 guidance cut: net sales now $2.950-$2.975B (prior $3.050-$3.075B); adjusted EPS $9.00-$9.15 (prior $9.30-$9.45).
Guidance reflects $190M FX headwind and ~$85M decline in COVID-19 sales; base business growth partially offsets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.